|
- [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for . . .
Almost 10 years after its discovery, [68 Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first 68 Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020
- LABEL - Food and Drug Administration
Ga 68 DOTATOC Injection is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors
- Dual targeting PET tracer [68Ga]Ga-PSFA-01 in patients with prostate . . .
Purpose: To assess the effectiveness of [68 Ga]Ga-PSFA-01 PET CT in detecting primary tumors and metastatic lesions in patients with prostate cancer (PCa), and to compare the results with those from [68 Ga]Ga-PSMA-11 PET CT and [68 Ga]Ga-FAPI-04 scans
- 68Ga-Based Radiopharmaceuticals: Production and Application Relationship
Small compounds, biological macromolecules as well as nano- and micro-particles have been successfully labeled with 68Ga, and the resulting agents demonstrated promising imaging capability pre-clinically and clinically [1,3–6]
- Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 . . .
Cyclotron produced [68Ga]Ga-PSMA-11 underwent full quality control, stability and sterility testing, and was implemented for human use at the University of Michigan as an Investigational New Drug through the US FDA and also at the Royal Prince Alfred Hospital (RPA)
- [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga . . . - PubMed
This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys (Ahx)-HBED-CC with the radionuclide 68 Ga, enabling specific imaging of tumor cells expressing PSMA Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response
- 68Ga-grazytracer PET for noninvasive assessment of response to . . .
To tackle the clinical challenge of noninvasively assessing immunotherapy efficacy in patients, here we used positron emission tomography (PET) with 68 Ga-grazytracer, which targets granzyme B,
- 68Ga-Based Radiopharmaceuticals: Production and Application . . .
The contribution of 68Ga to the promotion and expansion of clinical research and routine positron emission tomography (PET) for earlier better diagnostics and individualized medicine is considerable
|
|
|